| [1] |
Feng Siqi, Ni Yuchen, Hu Fengyi, Liu Yue, Ye Xiaofei, Guo Xiaojing.
Long-term post-marketing safety surveillance of cell therapy products: international experience and optimization pathways in China
[J]. Chinese Journal of Pharmacovigilance, 2026, 23(9): 975-981.
|
| [2] |
XU Zhuoxin, ZHANG Bing, ZHANG Xiaomeng, MENG Min, SA Rina.
Strategies for Pharmacovigilance in Medical Institutions Based on Closed-Loop Model of Risk Management
[J]. Chinese Journal of Pharmacovigilance, 2026, 23(4): 438-442.
|
| [3] |
SONG Yana, ZHAO Yan, LI Dong, ZHAO Yifei, ZHENG Lijia, ZHI Rui, DENG Gang.
Global Trends and China’s Practices Related to Medical Device Vigilance Systems
[J]. Chinese Journal of Pharmacovigilance, 2026, 23(3): 290-295.
|
| [4] |
ZHANG Wang, WANG Ningning, YANG Fang, GAO Yue, ZHOU Wei.
Reproductive Toxicity and Risk Control of Psoralea corylifolia Based on Systems Toxicology
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(9): 961-966.
|
| [5] |
SU Xian, LIU Wendong, HU Yangping, WANG Xiaohan, WANG Haixue.
Technical Highlights of Safety Monitoring Plans during Drug Clinical Trials
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(9): 1003-1007.
|
| [6] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
| [7] |
LI Dong, ZHAO Yan.
Roles of National Arthroplasty Registries in Post-Market Surveillance of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 640-644.
|
| [8] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
| [9] |
HU Jun.
Takeaways from the National Annual Reports on Adverse Drug Reaction Monitoring (2020-2024)
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(12): 1376-1379.
|
| [10] |
LI Dong, ZHANG Longying, SHEN Xiaohua, LIU Zhangpin, WU Zhengshan, ZHAO Yan.
Mandatory Post-Market Studies of Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(12): 1383-1387.
|
| [11] |
STRESE Sara, LAGERLUND Olof, SHEN Ling, AHNFELT Emelie, YUE Qunying, FLADVAD Malin.
WHODrug Global: a Validated, Regularly Updated and Standardised Drug Dictionary for Medicinal Information Coding
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(10): 1194-1200.
|
| [12] |
SUN Ximu, ZHOU Han, LI Yanming, GUO Peng, NIE Xiaolu.
Signal Mining and Analysis of ICIs-Associated Thrombocytopenia Adverse Events Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 23-28.
|
| [13] |
SUN Yixin, WANG Chen, YU Yuelin, GUO Peng, NIE Xiaolu.
Safety Surveillance for Vaccine-Induced Immune Thrombotic Thrombocytopenia: a Systematic Review
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 29-36.
|
| [14] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
| [15] |
SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng.
Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
|